GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Distribution » Sichuan Goldstone Asia Pharmaceutical Inc (SZSE:300434) » Definitions » Ending Cash Position

Sichuan Goldstone Asia Pharmaceutical (SZSE:300434) Ending Cash Position : ¥278 Mil (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Sichuan Goldstone Asia Pharmaceutical Ending Cash Position?

Sichuan Goldstone Asia Pharmaceutical's Ending Cash Position for the quarter that ended in Mar. 2025 was ¥278 Mil.

Sichuan Goldstone Asia Pharmaceutical's quarterly Ending Cash Position increased from Sep. 2024 (¥357 Mil) to Dec. 2024 (¥417 Mil) but then declined from Dec. 2024 (¥417 Mil) to Mar. 2025 (¥278 Mil).

Sichuan Goldstone Asia Pharmaceutical's annual Ending Cash Position increased from Dec. 2022 (¥436 Mil) to Dec. 2023 (¥546 Mil) but then declined from Dec. 2023 (¥546 Mil) to Dec. 2024 (¥417 Mil).


Sichuan Goldstone Asia Pharmaceutical Ending Cash Position Historical Data

The historical data trend for Sichuan Goldstone Asia Pharmaceutical's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Goldstone Asia Pharmaceutical Ending Cash Position Chart

Sichuan Goldstone Asia Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 410.76 234.72 436.22 545.90 417.24

Sichuan Goldstone Asia Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 444.14 262.54 357.38 417.24 278.15

Sichuan Goldstone Asia Pharmaceutical Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sichuan Goldstone Asia Pharmaceutical's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=545.899+-128.657
=417

Sichuan Goldstone Asia Pharmaceutical's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=417.292+-139.147
=278


Sichuan Goldstone Asia Pharmaceutical Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Sichuan Goldstone Asia Pharmaceutical's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Sichuan Goldstone Asia Pharmaceutical Business Description

Traded in Other Exchanges
N/A
Address
8 Jiayuan Road, 8th Floor, District A1, Dadi Xinguanghua Plaza, Chengdu, CHN, 610072
Sichuan Goldstone Asia Pharmaceutical Inc is engaged in development and application of steel-reinforced plastic composite pipe technology, providing customers with steel-reinforced plastic composite pipes from pipe structure, production process to construction technology. The company is also engaged in research and development, production and sales of medicines and health products.
Executives
Zheng Zhi Yong Director
Wei Bao Kang Directors, executives
Kuai Yi Xi Director
Chen Shao Jiang Executives
Lai Xing Feng Supervisors
Lin Qiang Directors, Directors, and Executives
Fu Hai Ying Directors, executives
Wang Shou Lun Supervisors
Li Run Xiu Supervisors

Sichuan Goldstone Asia Pharmaceutical Headlines

No Headlines